Dominican Scholar
Collected Faculty and Staff Scholarship

Faculty and Staff Scholarship

5-2-2017

Private sector opportunities and threats to achieving malaria
elimination in the Greater Mekong Subregion: results from malaria
outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand.
Kathryn A. O'Connell
ACTwatch Group

Vamsi Vasireddy
ACTwatch Group

Megan Littrell
ACTwatch Group

Andria Rusk
ACTwatch Group, andria.rusk@dominican.edu

ACTwatch Group

Survey: Let us know how this paper benefits you.
See next page for additional authors

Recommended Citation
O'Connell,
Kathryn A.; Vasireddy, Vamsi; Littrell, Megan; Rusk, Andria; ACTwatch Group;
https://doi.org/10.1186/s12936-017-1800-5
Phok, Sochea; Phanalasy, Saysana; Thein, Si Thu; and Likhitsup, Asawin, "Private sector
opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion:
results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand."
(2017). Collected Faculty and Staff Scholarship. 340.
https://doi.org/10.1186/s12936-017-1800-5

DOI

http://dx.doi.org/https://doi.org/10.1186/s12936-017-1800-5
This Article is brought to you for free and open access by the Faculty and Staff Scholarship at
Dominican Scholar. It has been accepted for inclusion in Collected Faculty and Staff Scholarship by
an authorized administrator of Dominican Scholar. For more information, please contact
michael.pujals@dominican.edu.

Authors
Kathryn A. O'Connell, Vamsi Vasireddy, Megan Littrell, Andria Rusk, ACTwatch Group, Sochea
Phok, Saysana Phanalasy, Si Thu Thein, and Asawin Likhitsup

This article is available at Dominican Scholar: https://scholar.dominican.edu/all-faculty/340

Malaria Journal

Private sector opportunities and threats
to achieving malaria elimination in the Greater
Mekong Subregion: results from malaria outlet
surveys in Cambodia, the Lao PDR, Myanmar,
and Thailand
ACTwatch Group et al.
ACTwatch Group et al. Malar J (2017) 16:180
DOI 10.1186/s12936-017-1800-5

ACTwatch Group et al. Malar J (2017) 16:180
DOI 10.1186/s12936-017-1800-5

Malaria Journal
Open Access

RESEARCH

Private sector opportunities and threats
to achieving malaria elimination in the Greater
Mekong Subregion: results from malaria outlet
surveys in Cambodia, the Lao PDR, Myanmar,
and Thailand
ACTwatch Group1*, Sochea Phok2, Saysana Phanalasy3, Si Thu Thein4 and Asawin Likhitsup5

Abstract
Background: The aim of this paper is to review multi-country evidence of private sector adherence to national regulations, guidelines, and quality-assurance standards for malaria case management and to document current coverage
of private sector engagement and support through ACTwatch outlet surveys implemented in 2015 and 2016.
Results: Over 76,168 outlets were screened, and approximately 6500 interviews were conducted (Cambodia,
N = 1303; the Lao People’s Democratic Republic (PDR), N = 724; Myanmar, N = 4395; and Thailand, N = 74). There
was diversity in the types of private sector outlets providing malaria treatment across countries, and the extent to
which they were authorized to test and treat for malaria differed. Among outlets stocking at least one anti-malarial,
public sector availability of the first-line treatment for uncomplicated Plasmodium falciparum or Plasmodium vivax
malaria was >75%. In the anti-malarial stocking private sector, first-line treatment availability was variable (Cambodia, 70.9%; the Lao PDR, 40.8%; Myanmar P. falciparum = 42.7%, P. vivax = 19.6%; Thailand P. falciparum = 19.6%, P.
vivax = 73.3%), as was availability of second-line treatment (the Lao PDR, 74.9%; Thailand, 39.1%; Myanmar, 19.8%; and
Cambodia, 0.7%). Treatment not in the National Treatment Guidelines (NTGs) was most common in Myanmar (35.8%)
and Cambodia (34.0%), and was typically stocked by the informal sector. The majority of anti-malarials distributed in
Cambodia and Myanmar were first-line P. falciparum or P. vivax treatments (90.3% and 77.1%, respectively), however,
8.8% of the market share in Cambodia was treatment not in the NTGs (namely chloroquine) and 17.6% in Myanmar
(namely oral artemisinin monotherapy). In the Lao PDR, approximately 9 in 10 anti-malarials distributed in the private
sector were second-line treatments—typically locally manufactured chloroquine. In Cambodia, 90% of anti-malarials
were distributed through outlets that had confirmatory testing available. Over half of all anti-malarial distribution was
by outlets that did not have confirmatory testing available in the Lao PDR (54%) and Myanmar (59%). Availability of
quality-assured rapid diagnostic tests (RDT) amongst the RDT-stocking public sector ranged from 99.3% in the Lao
PDR to 80.1% in Cambodia. In Cambodia, the Lao PDR, and Myanmar, less than 50% of the private sector reportedly
received engagement (access to subsidized commodities, supervision, training or caseload reporting), which was
most common among private health facilities and pharmacies.
Conclusions: Findings from this multi-country study suggest that Cambodia, the Lao PDR, Myanmar, and Thailand
are generally in alignment with national regulations, treatment guidelines, and quality-assurance standards. However,
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important gaps persist in the private sector which pose a threat to national malaria control and elimination goals.
Several options are discussed to help align the private sector anti-malarial market with national elimination strategies.
Keywords: Anti-malarial, Private sector, Greater Mekong Subregion (GMS), First-line, Second-line, Market share,
Availability, RDT

Background
Malaria elimination is the goal of all countries in the
Greater Mekong Subregion (GMS), with accelerated
achievement a priority due to the emergence and spread
of artemisinin drug resistant parasites. The World Health
Organization (WHO) Strategy for Malaria Elimination in
the GMS (2015–2030) sets a target of malaria elimination
in all GMS countries by 2030 and Plasmodium falciparum malaria by 2025 [1]. Appropriate case management
of all suspected malaria cases, including early confirmatory diagnosis and prompt treatment with effective, firstline anti-malarial medicines, is essential to achieving the
WHO elimination goals.
National programmes across the region have defined
National Treatment Guidelines (NTG) stipulating the use
of different first- and second-line treatments for uncomplicated and severe malaria (Table 1) for any Plasmodium species infection. These guidelines vary by country
in part due to the need to continually update guidelines
based on the latest evidence regarding anti-malarial drug
tolerance, therapeutic efficacy, and resistance [2].
Achieving universal coverage with quality-assured
diagnostics and anti-malarials requires three channels
of service delivery to be considered: public, private, and
community-based [1]. It is acknowledged by the WHO
that the optimal mix of these channels will vary between
and within countries and in elimination settings, and

that the roles for each channel should be reviewed and
defined, depending on the country situation and local
conditions, to ensure optimal case management, surveillance, and reporting in all areas.
In the GMS, the role of the private sector has been
recognized as an important source of anti-malarial
treatment in many countries, including Cambodia,
Myanmar, and the Lao People’s Democratic Republic
(PDR). Supply-side surveys have illustrated how most
anti-malarial medicines are distributed through the
private sector [3, 4], and these findings are complemented by population-based surveys from these countries which illustrate that febrile patients commonly
seek treatment in the private sector [5–7]. While the
private sector is relevant across the region, the specific
types of outlets that provide malaria testing and treatment differs by country. In addition, national policies
vary with respect to the specific providers and outlet
types that are authorized to test for and treat malaria
(Table 2). In the Lao PDR, all private for-profit health
facilities and pharmacies are permitted to provide
malaria testing and treatment, whereas in Cambodia only private health facilities and registered pharmacies in the Public–Private Mix (PPM) programme
are authorized to test and treat. In grocery stores and
general retailers, and among itinerant drug vendors,
the sale of anti-malarials is prohibited by national

Table 1 National Treatment Guidelines Cambodia, Lao PDR, Myanmar, and Thailand
Country

Year

First-line Pf

Cambodia

2014

Lao PDR

2013

Fixed-dose combination (FDC) artesunate-mefloquine
(ASMQ) + primaquine or dihydroartemisinin-piperaquine + primaquine (DHA-PPQ)

Myanmar

Thailand

a
b

First-line Pv

First-line severe malaria

Second-line

Artesunate Intravenous
(IV)/Intramuscular (IM) or
Artemether IV/IM

Pf/Pv: Quinine + doxycycline or
tetracycline

Artemether–Lumefantrine (AL) + primaquine

Artesunate IV/IM

Pf: Quinine + doxycycline
Pv: Chloroquine
Severe: Quinine IV/IM

2012

AL or ASMQ or DHA
PPQ + primaquinea

Chloroquine + primaquine

Artesunate IV/IM

Pf: Alternative first-line artemisininbased combination medicines or
artesunate + either doxycycline,
tetracycline, or clindamycin
Severe: Artemether IV/IM or Quinine
IV/IM

2014

ASMQ or DHA P
 PQb + primaquine

Chloroquine + primaquine

Artesunate IV/IM

Pf: Quinine + doxycycline, or artesunate + doxycycline or clindamycin
Pv: Chloroquine
Severe: Quinine IV/IM

In late 2015, the Myanmar NTGs changed to AL + primaquine

In late 2015, the Thailand malaria treatment guidelines changed in eight provinces to stipulate use of DHA PPQ, with a single dose of primaquine (30 mg) on day 1
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Table 2 Outlet type definitions
Outlet type

Description

Authorized to test and treat
Cambodia Lao PDR Myanmar Thailand

Public sector
Public health facility

Public health facilities include government health facilities as well as
private not-for-profit facilities

×

×

×

×

Community health
worker

Community health workers (CHW) are community-based volunteers
×
typically linked with government or non-government not-for-profit
organizations and are equipped with anti-malarial treatment and
malaria RDT. CHW receive formal training on malaria case management

×

×

×

Private health facility

Private for-profit health laboratories, clinics, and hospitals that provide
healthcare to the general public

×

×

×

Pharmacy

Pharmacies are typically licensed and regulated by a national regulatory
×
authority and are staffed by pharmacists and qualified health practitioners

×

×

Drug store

Drug stalls in rural markets and shops that primarily sell medicines. These
outlets are not guaranteed to be staffed by qualified health dispensers/
practitioners and are not licensed by a national regulatory authority.
Drug stores are not found in Myanmar

General retailer

General retailers are grocery stores and village shops that sell fast-moving
consumer goods, food, and provisions

×

Itinerant drug vendor

Mobile drug vendors found primarily in rural areas, typically working
within the radius of their home or travelling to nearby villages to deliver
medicines. They are not registered with any national regulatory authority

×

Private sector

authorities in Cambodia, the Lao PDR, and Thailand
but not in Myanmar. In Thailand, the private sector is
almost completely prohibited to provide anti-malarials
or confirmatory testing, and only certain private hospitals are permitted to provide testing and treatment on a
case-by-case basis.
Although the private sector plays a significant role in
malaria case management throughout these countries,
several challenges have been noted with the performance
of this sector. There may be a lack of knowledge among
providers on where to refer patients with more severe
conditions and limited provision of information to accompany the sale of treatments [8]. Available treatments may
be clinically inappropriate and/or administered in doses
that are outside of the therapeutic range [8]. Private sector providers may also have little financial incentive to
distribute first-line anti-malarials for treatment and will
instead sell a wide variety of low-cost anti-malarials [9,
10]. Similarly, while malaria rapid diagnostic tests (RDT)
can accurately diagnose malaria and prevent the unnecessary use of artemisinin-based combination therapy
(ACT), private sector providers may be reluctant to provide a confirmatory test given financial disincentives and a
desire to profit through the sale of anti-malarial products
[11, 12]. Moreover, providers, especially in the informal
or unregulated sector, often have less training, including
training on medicines that are not in the NTGs, which are
subject to frequent changes given evolving drug resistance

in the region [13]. These documented challenges with
the private sector readiness and performance for malaria
case management threaten recent elimination goals and
strategies. To meet these elimination goals, it is imperative that the private sector is in alignment with national
regulations, guidelines, and quality-assurance standards
for malaria case management.
Given the role and diversity of the private sector
across different countries and challenges with its performance, several efforts have been made to support
and engage private sector providers to ensure high quality care or to prohibit this sector entirely from providing
malaria case management services. This has included
a PPM programme in Cambodia (since 2011) and the
Lao PDR (since 2008) to regulate and license private
for-profit facilities and pharmacies and to provide subsidized malaria commodities, training, and supervision.
In Myanmar, private sector strengthening through the
Artemisinin Monotherapy Replacement (AMTR) Project has been in place since 2012 to increase access to
subsidized first-line treatments, including supportive
interventions targeted at the informal private sector.
In Thailand, the government banned the sale of antimalarials in the private sector in 1995 to control the
spread of drug resistant parasites. To date, the comparative performance of the different private sector antimalarial markets across these countries has yet to be
investigated.
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Given the popularity of private sector providers for
health services, the private sector can be an asset for
accelerating progress towards national malaria elimination goals. However, private providers operating outside
of regulation, national guidelines, and quality-assurance
standards pose a serious threat to elimination goals [14].
Market landscaping is essential in an elimination setting
[15] as it provides insights into the breadth and quality
of private sector diagnosis, treatment, and reporting and
identifies gaps and challenges in each country context.
Information provided through a market landscape can
help prioritize the specific outlets to target and identify
the extent to which outlets are operating in accordance
with the current regulatory environment. Evidence can
be adapted to create strategies for engagement with the
private sector within each country.
The aim of this paper is to review multi-country evidence of private sector adherence to national regulations, guidelines, and quality-assurance standards for
malaria case management and to document current
coverage of private sector engagement and support. This
information can be used to target appropriate strategies
designed to ensure private provider alignment with and
contributions to national malaria control and elimination goals.

Methods
ACTwatch was launched in 2008 by Population Services International (PSI) with support from the Bill and
Melinda Gates Foundation. Details about the ACTwatch
project and methodology have been published elsewhere
[16, 17]. The goal of the project is to generate timely, relevant, and high quality evidence about anti-malarial and
diagnostic markets for policy makers, donors, and implementing organizations. As of 2016, ACTwatch had gathered data from a total of 12 malaria endemic countries
in sub-Saharan Africa and the GMS. This paper presents
data from outlet surveys in four GMS countries collected
in 2015 and 2016.
Design and sampling

The ACTwatch outlet surveys were nationally-representative or sub-national surveys conducted among a sample
of outlets stocking anti-malarial medicines and diagnostics. All categories of outlets with the potential to stock
anti-malarials in both the public and private sectors were
included in the study. In the public sector, this included
government health facilities (hospitals, centres, clinics, and posts) and community health workers (CHW).
Outlets sampled in the private sector included private
for-profit health facilities (hospitals, centres, and clinics), pharmacies, drug stores, general retailers, and itinerant drug vendors (mobile vendors without a fixed service
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delivery point). Drug stores were not present in Myanmar and thus not represented as an outlet category. In
Myanmar, permission was not received to include public
health facilities, so these were excluded from the study.
Probability proportional to size (PPS) sampling was
used to select administrative units for the surveys using
each country’s national population sampling frames.
Administrative units were clusters that typically had a
population size of 10,000–15,000 inhabitants. As lists of
all potentially eligible outlets were not routinely available,
an outlet census was used to identify outlets for inclusion in the survey. To identify outlets, interviewers would
walk systematically through each of the selected clusters looking for relevant outlets. Lists of registered outlets, such as public health facilities or pharmacies, were
obtained prior to the data collection and used to help
identify outlets. Local maps were also used to identify the
catchment area of each selected cluster within a country.
To identify itinerant drug vendors, congregation points
or locations were identified using key informant interviews. These providers were approached by interviewers
and asked if they had already participated in the survey
to avoid duplication. Within each selected cluster, all
outlet types with the potential to provide anti-malarials
to consumers were screened. Outlets were eligible for a
provider interview and malaria product audit if they met
at least one of three study criteria: (1) one or more antimalarials reportedly in stock on the day of the survey; (2)
one or more anti-malarials reportedly in stock within the
3 months preceding the survey; and/or (3) malaria RDT
in stock or malaria microscopy available on the day of the
survey. The sampling strategy and stratification is summarized in Table 3.
In the Lao PDR and Thailand, boundaries for the outlet census were extended to higher administrative units
to cover a larger area for key outlets or areas. In the Lao
PDR, this included oversampling of pharmacies and
private for-profit health facilities at the district level. In
Thailand, the geographic area for sampling outlets was
extended to the district level for districts with an international border. This booster sampling strategy was used to
expand the census and screening of pharmacies.
Myanmar had four geopolitical zones that were used
as research domains. Since 2012, yearly sub-national
surveys had been conducted in the Central and Eastern
parts of the country as a means to monitor the AMTR
project. The Eastern part of the country had been previously described as the AMTR project intervention area,
given that several supportive interventions have been
implemented in this part of the country [3, 18]. The Central domain had been described as the ‘Comparison’ area
to observed differences between this area and the Eastern domain, where AMTR activities had been in place.

ACTwatch Group et al. Malar J (2017) 16:180

Page 6 of 22

Table 3 Summary of sampling procedures across the study countries
Cambodia

Lao PDR

Dates of data
collection

August 17th to October 1st, 2015

November 18th to
August 18th, 2015, to
December 29th, 2015
January 4th, 2016

February 9th to March
22nd, 2016

Stratification

National, two domains based on the WHO evidence about artemisinin resistance to define a
3-tier stratification [45]:
Tier 1 provinces (prioritized for immediate
multifaceted response to contain or eliminate
resistance)
Tier 2 provinces (prioritized for intensified malaria
control to reduce transmission and/or limit
the risk of emergence or spread of resistant
parasites)

Sub-national, five
southern provinces

National, four geographic
domains:
Eastern domain
Central domain
Western domain
Coastal domain

Sub-national, two geographic domains:
Thai–Cambodia border
areas
Thai–Myanmar border
areas

Number of
clusters

160 Communes

77 Village groups

808 Wards and village
tracts

194 Sub-districts

Cambodia and Thailand had two research domains, and
the study was stratified to deliver estimates for relevant
research domains. Both Thailand and the Lao PDR were
sub-national surveys, while Cambodia and Myanmar
were nationally representative.
The study was designed to generate estimates for
key market indicators within each domain. Minimum
sample size requirements were calculated to estimate,
with ±10% precision, the following indicators: (1) the
proportion of private sector outlets with ACT medicine
available, among outlets with anti-malarial(s) in stock on
the day of the survey; and (2) proportion of outlets with
malaria blood testing (RDT or microscopy) available,
among outlets with anti-malarial(s) in stock on the day
of the survey or within the past 3 months. The number
of study clusters was calculated for each research domain
based on the required number of anti-malarial stocking
outlets and assumptions about the number of anti-malarial stocking outlets per cluster. Sample size requirements
for follow-up surveys were calculated using information
from previous survey rounds where available.
Data collection periods varied by country and over
time but were typically implemented during the peak
malaria transmission season for each country and lasted
approximately 6 weeks, with the exception of Myanmar
which took over 4 months.
Training and data collection

Interviewer training consisted of standardized classroom
presentations and exercises as well as a field exercise.
Additional training was provided for supervisors and
quality-controllers focused on field monitoring, verification visits, and census procedures. Data collection teams
were provided with a list of selected clusters and official maps that illustrated administrative boundaries. In
each selected cluster, fieldworkers conducted a full enumeration of all outlets that had the potential to provide

Myanmar

Thailand

anti-malarials. This included enumeration of outlets with
a physical location, as well as identification of CHW and
itinerant drug vendors using local informants.
Quality control measures implemented during data collection included questionnaire review by supervisors and
interview verification visits conducted by quality controllers to between 10 and 20% of all outlets. Up to three
visits were made to all outlets to complete the screening
process, audit, and provider interview as needed.
As previously mentioned, a series of screening questions were administered at all outlets to determine eligibility for the survey. Following informed consent
procedures, an audit of all available anti-malarial medicines and RDT was conducted. In addition to the product audit, a series of questions were administered to the
senior-most provider regarding malaria case management knowledge and practices. Questions were also
administered to providers to measure the extent to which
they reportedly received supervision, training on NTG or
malaria diagnostics, access to subsidized anti-malarials,
and caseload reporting. Questions regarding access to
subsidized anti-malarials and RDT were not administered in Myanmar.
All surveys were paper-based with the exception of
Cambodia, where data were collected using Android
phones and forms created using DroidDB (© SYWARE,
Inc., Cambridge, MA, USA). Interviews were conducted
in the local language using questionnaires that were
translated from English to the local language and back to
English to confirm translations.
Data analysis

Double data entry was conducted using Microsoft
Access (Microsoft Corporation, Redmond, WA, USA)
with built-in range and consistency checks. Data were
analysed across survey rounds using Stata (StataCorp
College Station, TX). Sampling weights were calculated

ACTwatch Group et al. Malar J (2017) 16:180
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as the inverse of the probability of cluster selection. All
point estimates were weighted using survey settings and
all standard errors calculated taking account of the clustered and stratified sampling strategy.
Standard indicators were constructed according to
definitions applied across the ACTwatch project and
have been described in detail elsewhere [17, 19]. Briefly,
anti-malarials identified during the outlet drug audit
were classified as treatments found in the NTGs or not,
and within the NTGs as first-line or second-line treatment for P. falciparum and P. vivax malaria. Drug audit
information used for the classification included active
ingredients, formulation, and strengths. Official NTGs
in use at the time of the survey were used for the classification. Availability of NTG treatments at the outlet level
was defined as availability of any component of what
may be a multi-drug regimen. However, when one of the
drugs was not an anti-malarial (e.g. antibiotics), the antimalarial was only classified as a medicine in the NTGs if
the partner antibiotic was available as well. The rationale
for this classification is that if the anti-malarial medicine was present without the antibiotic, the anti-malarial
could not be administered according to the NTGs. Firstline and second-line treatment availability, and treatments not in the NTGs, were restricted to those outlets
that had anti-malarials in stock.
RDT were classified as quality-assured or non qualityassured. Quality-assured RDT were RDT that were in
compliance with the Global Fund Quality Assurance
Policy on the Global Fund list of approved RDT products
for procurement. The product catalogue number (PCN)
was used to identify products on the Global Fund list of
approved products. Availability of quality-assured RDT
and non quality-assured RDT was restricted to outlets
with an RDT in stock.

Anti-malarial market composition was defined as the
proportion of outlets of each type, among outlets with antimalarials in stock on the day of the survey. Market share,
or the relative distribution of anti-malarials to individual
consumers recorded in the drug audit, was standardized
to allow meaningful comparisons between anti-malarials
with different treatment courses and different formulations. The adult equivalent treatment dose (AETD) was
defined as the amount of active ingredient required to
treat an adult weighing 60 kg according to WHO treatment guidelines [2]. Provider reports on the amount of
the drug sold or distributed during the week preceding the
survey were used to calculate volumes according to type
of anti-malarial. The volume of each drug was calculated
as the number of AETDs that were reported to have been
sold/distributed during the week preceding the survey.
Measures of volume included all dosage forms to provide a
complete assessment of anti-malarial market share.

Results
In total, 76,168 outlets were screened for availability of
anti-malarials and malaria diagnostics during the 2015
and 2016 outlet surveys: Cambodia (N = 26,664), the
Lao PDR (N = 7586), Myanmar (N = 28,267) and Thailand (N = 13,651). For all surveys, the majority of outlets screened and with completed interviews were private
sector outlets. Approximately 6500 full interviews were
conducted (Cambodia, N = 1303; the Lao PDR, N = 724;
Myanmar, N = 4395; and Thailand, N = 74) where a total
of 11,437 anti-malarials and 4043 RDT were audited.
Refer to Table 4 for a full breakdown of the screening and
audit results for each country by sector.
Across the facility types, availability of at least one antimalarial among all screened outlets varied. Anti-malarials were commonly available in public health facilities in

Table 4 Results of the outlet census and AM/RDT product audit (N)
Cambodia

Lao PDR

Myanmar

Public

Private

Public

Private

Public

b

Thailand
Private

Public

Private
13,296

Screened

604

26,060

558

7028

2737

25,530

355

Eligiblea

558

750

258

467

1449

2948

79

25

Interviewed

557

746

258

466

1463

2932

49

25

Anti-malarial(s) in stock

467

391

236

394

1263

2596

72

19

75

179

19

30

119

294

0

1

Anti-malarial(s) out of stock, in
stock in the past 3 months

15

176

3

42

81

42

7

5

Anti-malarials audited

Malaria testing available

759

531

773

217

4227

4642

247

41

Malaria RDT audited

605

592

893

266

1188

447

44

8

a

Outlets are eligible for the outlet survey if they either (1) have anti-malarials currently in stock at the time of the interview, (2) have stocked anti-malarials in the past
3 months, or (3) currently stock malaria microscopy or malaria RDT

b

In Myanmar, public health facilities were not included in the study. The numbers in this table reflect the results of the outlet census and audit of CHW in Myanmar

ACTwatch Group et al. Malar J (2017) 16:180

Cambodia (77.9%), the Lao PDR (97.8%) and in Thailand
(94.9%). Private sector availability was lower, and most
common among private for-profit facilities in Cambodia (31.0%), the Lao PDR (36.2%) and Myanmar (50.4%).
In the Lao PDR, 70.6% of pharmacies had at least one
anti-malarial in stock. Across other private sector outlet types, anti-malarials were less commonly available
(<20%) (Additional file 1).
Market composition

Figure 1 shows that, in terms of absolute number of
places where anti-malarial medicines were available,
there was considerable diversity in the types of outlets providing malaria treatment across countries. In
Cambodia, the private sector market composition was
comprised primarily of private for-profit facilities and
itinerant drug vendors. In the Lao PDR and Thailand,
the private sector service delivery points were typically
pharmacies. In Myanmar, the private sector composition comprised primarily of general retailers, but itinerant drug vendors and pharmacies were also common. In
the public sector, across Cambodia, the Lao PDR, and
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Myanmar, CHW composed just over 40% of the market composition, and findings were similar between
these three countries. In Thailand, public health facilities were the most common type of outlet stocking antimalarials (87.6%), but in the Lao PDR and Cambodia,
public health facilities were less than 25% of the antimalarial service delivery points.
The outer pie chart in Fig. 1 illustrates outlets that are
authorized to test for and treat malaria, according to
national policy. All of the private sector outlets in Thailand were not authorized to test for or treat malaria. In
Cambodia, half of the private sector anti-malarial market
composition consisted of outlets that were not authorized to test for or treat malaria, and in the Lao PDR this
included one in four private sector anti-malarial stocking
outlets. In contrast, all private sector outlets in Myanmar
were authorized to test for and treat malaria.
Anti‑malarial availability

Availability of first-line, second-line, and treatment not
indicated in the NTGs among anti-malarial stocking
outlets is shown in Fig. 2. Treatment categories for each

Inner pie chart legend
Public Health Facility

Cambodia, N=858

Lao PDR, N=402

Community Health Worker
Private Health Facility
Pharmacy
Drug Store
General Retailer
Itinerant Drug Vendor

Outlet pie chart legend

Myanmar*, N=3,859
Authorised to test and treat if
part of the PPM programme
Not authorised to test or treat

*In Myanmar, this excludes public health facilities, which were
not included in the study

Fig. 1 Anti-malarial market composition

Thailand, N=87

PERCENT OF ANTI-MALARIAL STOCKING OUTLETS

ACTwatch Group et al. Malar J (2017) 16:180
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100
90
80
70
60
50
40
30
20
10
0

Public
N=467

Private
N=858

Cambodia

Public
N=236

Private
N=394

Public
N=1,263

Lao PDR

First-line Pf

First-line Pv

Private
N=2,596

Public
N=72

Myanmar

First-line Severe

Second-line

Private
N=19
Thailand

Not NTG

Fig. 2 Anti-malarial availability in the public and private sectors

country are defined in Table 2. Availability of NTG treatments at the outlet level were defined as availability of
any component of what may be a multi-drug regimen
according to each country’s recommended guidelines.
Public sector

Among outlets stocking at least one anti-malarial in the
public sector, availability of any component of the firstline treatment for uncomplicated P. falciparum or P.
vivax malaria was greater than 85% and highest in Cambodia, where there was almost universal coverage (99%).
One exception to this was found among CHW in Myanmar, where slightly less than three-quarters of these outlets had any component of the first-line treatment for P.
vivax available (74.5%). Availability of any component of
the first-line treatment for severe malaria was less than
5% of the anti-malarial stocking public sector in Cambodia, the Lao PDR, and Myanmar. Stocking rates of
the first-line treatment for severe malaria were slightly
higher in Thailand’s public sector (18.1%).
In the anti-malarial stocking public sector, availability
of any component of the second-line treatment was low
in Cambodia (2.5%), the Lao PDR (12%), and Myanmar
(12%). In Thailand, around one in three public sector
outlets were stocking any component of the second-line
treatment (31.7%). Availability of treatment not in the
NTGs was generally less than 5% across Cambodia, the
Lao PDR, and Myanmar’s public sector. In Thailand,
18.2% of the anti-malarial stocking public sector had
treatments that were not in the NTGs.

Private sector

Among outlets stocking at least one anti-malarial in the
private sector, availability of any component of the firstline treatment for uncomplicated P. falciparum or P.
vivax malaria was variable across countries and lower
than the public sector. In Cambodia, availability of the
first-line treatment for P. falciparum or P. vivax (ACT)
was 70.9%, and in the Lao PDR, less than half of the antimalarial stocking outlets had the first-line P. falciparum
or P. vivax treatment (ACT) in stock (40.8%). In Myanmar and Thailand, less than half of the private sector had
any component of P. falciparum treatment (ACT and/or
primaquine) (42.7 and 19.6% respectively). Availability of
any component of P. vivax treatment (chloroquine and/
or primaquine) was higher in these countries (56.2 and
73.3%, respectively). Availability of any component of
the first-line treatment for severe malaria was generally
less than 5% of the anti-malarial stocking private sector
across all countries but was slightly higher in Thailand
(10.3%).
In the private sector, across all countries, availability
of any component of the second-line treatment among
anti-malarial stocking outlets was variable and highest
in the Lao PDR (74.9%) followed by Thailand (39.1%).
In these countries, availability of second-line treatment
was greater than availability of the first-line treatment
for uncomplicated malaria. In Myanmar, second-line
treatment was available in one in five anti-malarial stocking private sector outlets (19.8%) and rarely present in
Cambodia (0.7%). The types of second-line treatment
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medicines that were available were different across countries. In the Lao PDR, this was predominately secondline treatment for P. vivax malaria (chloroquine tablets,
branded as Maraquin®) and Maraquin was included in
the national list of registered medicines. In Myanmar,
this was second-line treatment for severe malaria (quinine and artemether liquid injections), and in Thailand,
this was second-line treatment for P. falciparum malaria
(quinine + doxycycline tablets).
Approximately one in three private sector outlets in
Cambodia (34.0%) and Myanmar (35.8%) stocked medicines that were not included in the NTGs. In Cambodia, these medicines were most commonly chloroquine
tablets, artemisinin piperaquine tablets, and non-FDC
artesunate mefloquine tablets. In Myanmar, these medicines were commonly oral artemisinin monotherapy. See
Additional file 2 for a comprehensive list of all audited
anti-malarials that were not included in the NTGs.
Types of private sector outlets stocking non‑first‑line
treatments

Table 5 illustrates the availability of any component of
the second-line treatment and treatment not included
in the NTGs among anti-malarial stocking private sector outlet types. Availability of second-line treatment
was most common among pharmacies (the Lao PDR,
72.4%; Myanmar, 27.2%; and Thailand, 28.1%) and itinerant drug vendors (the Lao PDR, 57.6%; Myanmar, 46.9%).
Private for-profit facilities were also found to commonly
stock any component of the second-line treatment in
some countries (the Lao PDR, 49.3%; Thailand, 70.0%).
Availability of private sector second-line treatment was
observed across all outlets in the Lao PDR and was rarely
found in Cambodia’s private sector.
Availability of treatment not in the NTGs was most
common among itinerant drug vendors (Cambodia,
48.4%; the Lao PDR, 57.6%; Myanmar, 29.5%) and general
retailers (Cambodia, 100%; Myanmar, 43.0%). Availability of treatment not in the NTGs was common (>20%)
across all private sector outlet types in Myanmar.
Anti‑malarial market share

Figure 3 shows the market share of different categories of anti-malarials sold or distributed in the 7 days
prior to the survey. The private sector played a larger
role than the public sector in the distribution of antimalarials. The majority of anti-malarials distributed in
Cambodia and Myanmar were first-line P. falciparum
or P. vivax treatments (90.3 and 77.1% respectively).
In the Lao PDR, only 37% of the anti-malarial market share was first-line treatment for P. falciparum or
P. vivax malaria. In all three countries, public sector
market share was dominated by first-line P. falciparum
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or P. vivax treatment. In the private sector, the antimalarials distributed included second-line treatment
and treatment not in the NTGs. In the private sector
in Cambodia and Myanmar, 8.8 and 17.6% of national
anti-malarial market share, respectively, were treatment not in the NTGs. In the Lao PDR, 59.0% of
national market share was private sector second-line
treatment. Approximately 9 in 10 anti-malarials distributed in the Lao PDR’s private sector were secondline treatments.
Private‑sector anti‑malarials not included in national
treatment guidelines

Additional file 2 includes a list of all audited anti-malarials that were not indicated in NTGs for each of the
study countries. Product characteristics such as generic
name, formulation, brand name, manufacturer, country
of manufacturer, registration status, number of products audited, and outlet type are described. There were
9 unique products audited in Cambodia, 4 in the Lao
PDR, 26 in Myanmar, and 3 in Thailand. All anti-malarials except for 2 (Mephaquin® manufactured by Mepha in
Switzerland and M
 alanil® manufactured by Glaxosmithkline in Canada) were manufactured in Asian countries
(China, India, the Lao PDR, Myanmar, Pakistan, Thailand, Vietnam).
In Cambodia, all audited anti-malarials that were not
indicated in the NTGs were either artemisinin piperaquine tablets (n = 31), artesunate tablets (n = 1),
chloroquine tablets (n = 67), or non-FDC artesunate
mefloquine tablets (n = 27). No audited products in
Cambodia were manufactured locally, and only 1 was
included in the national list of registered medicines
(chloroquine tablets manufactured by Acdhon). In the
Lao PDR, the majority of products audited that were
not in the Lao PDR NTGs included chloroquine injections (n = 45) and syrups (n = 4). The chloroquine
injection audited was Malacin® and was included in the
national list of registered medicines, while the chloroquine syrup was branded 
Chloquine® and, although
manufactured locally in the Lao PDR, was not included
in the list of registered medicines. In Myanmar, most
products audited were artemether (n = 57), artesunate
(n = 891), and SP tablets (n = 66). Of the artesunate
tablets audited, 88% (n = 784) were manufactured by
Mediplantex® in Vietnam. Several products (unbranded
artesunate and mefloquine tablets, and SP P
 yrixine®)
were manufactured locally by Myanmar/Tatmadaw
Pharmaceutical Factory. None of these aforementioned
products found in Myanmar were included in the
national list of registered medicines. There were only 3
products audited in Thailand that were not included in
the NTGs.
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Table 5 Percentage of anti-malarial stocking private sector outlets with non-first-line anti-malarials available

Cambodia
Second-line
Not in NTGs
Lao PDR
Second-line
Not in NTGs
Myanmar
Second-line
Not in NTGs
Thailand
Second-line
Not in NTGs
a

Private for-profit health facility
% (CI)

Pharmacy
% (CI)

Drug store
% (CI)

General retailer
% (CI)

Itinerant drug vendor
% (CI)

Private sector total
% (CI)

N = 186

N = 45

N = 22

N = 29

N = 109

N = 391

(0.1, 2.0)

–

(1.9, 21.4)

–

(0.1, 3.7)

(0.2, 2.2)

12.8

16.3

45.3

100.0

48.4

34.0

(7.8, 20.4)

(9.0, 27.7)

(26.1, 66.1)

–

(38.2, 58.6)

(26.4, 42.5)

N = 56

N = 309

N=3

N = 23

N=3

N = 394

(33.7, 65.0)

(64.8, 78.9)

–

(83.0, 99.5)

(40.9, 72.8)

(68.6, 80.3)

11.1

15.3

0.0

0.0

57.6

12.8

(5.4, 21.5)

(10.4, 21.9)

–

–

(40.9, 72.8)

(8.9, 18.2)

N = 314

N = 522

N/Aa

N = 1341

N = 419

N = 2596

(9.2, 21.9)

(20.8, 33.5)

(3.4, 9.0)

(40.7, 53.1)

(16.3, 23.3)

20.3

43.0

43.0

29.5

35.8

(13.8, 26.8)

(35.6, 50.4)

(36.7, 49.3)

(23.0, 36.0)

(31.6, 39.9)

N=9

N = 10

N=0

N=0

N=0

N = 19

(23.8, 94.6)

(10.5, 56.7)

–

–

–

(19.6, 62.9)

48.1

0.0

–

–

–

12.6

(13.7, 84.4)

–

–

–

–

(3.2, 38.6)

0.3

0.0

49.3

6.8

72.4

15.6

100.0

27.2

70.0

–
–

28.1

–

0.0

96.9

6.2

–

0.6

0.7

57.6

74.9

46.9

19.8

–

39.1

Drug stores do not exist in Myanmar
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Fig. 3 Anti-malarial market share in the public and private sectors

Malaria confirmatory testing availability and types of RDT
products

Availability of any test among the anti-malarial stocking public health facilities was greater than 90% across
Cambodia (98.8%), the Lao PDR (90.8%) and Thailand
(94.7%). Availability among anti-malarial stocking CHW

was greater than 80% in Cambodia (91.4%), the Lao PDR
(81.8%) and Myanmar (81.6%). The private sector ranged
from 87.2% of anti-malarial stocking private for-profit
facilities in Cambodia, 78.6% in the Lao PDR, 58.0% in
Myanmar and 91.2% in Thailand. Among anti-malarial
stocking pharmacies, availability ranged from 74.8% in
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Cambodia, 56.6% in the Lao PDR, 15.6% in Myanmar.
Availability was 17.9% among anti-malarial stocking itinerant drug vendors in Myanmar and less than 5% of general retailers in the Lao PDR and Myanmar (Fig. 4).
Among outlets stocking any RDT, availability of malaria
RDT with and without Global Fund Quality Assurance
status and according to parasite species detection among
RDT-stocking outlets is shown in Fig. 5. Amongst the
RDT-stocking public sector, availability of quality-assured
RDT ranged from 99.3% in the Lao PDR to 80.1% in Cambodia. Public sector availability of non quality-assured
RDT was 38.1% in Cambodia, 20.8% in Thailand, and was
negligible or non-existent across the other countries.
Amongst the RDT-stocking private sector, 100% of private facilities in Thailand had quality-assured RDT in stock
and almost all private facilities in the Lao PDR (94%). In
Cambodia and Myanmar, 3 in 4 private sector RDT-stocking facilities had quality-assured RDT available. Private sector availability of non quality-assured RDT was observed
in 25.7% of facilities in Cambodia and 17.2% in Myanmar.
Private sector availability of non quality-assured RDT was
negligible or non-existent in the Lao PDR and Thailand.
Almost all RDT audited in the four countries could
detect P. falciparum and either P. vivax (Pf/Pv) or other
species (Pf/Pan). Approximately three-quarters of RDTstocking outlets in Cambodia stocked Pf/Pv RDT (public 81.0%, private 76.3%) and one-quarter stocked Pf/Pan
(public 37.7%, private 24.7%). Almost all RDT-stocking
outlets in the Lao PDR stocked Pf/Pv RDT (public 99.4%,
private 98.9%). Similarly, outlets stocking RDT in Myanmar’s public sector almost exclusively stocked RDT that

could detect Pf/Pv (96.3%), while 76.5% of private sector
outlets stocked Pf/Pv RDT and 18.6% stocked Pf/Pan.
All public and private RDT-stocking outlets in Thailand
stocked Pf/Pan RDT.
Anti‑malarial market share: volumes distributed in outlets
with and without confirmatory testing

In Cambodia, 90% of all anti-malarials distributed were
distributed by outlets that had confirmatory testing available (Fig. 6). This includes all anti-malarials distributed by
public health facilities and most anti-malarials distributed
by CHWs. Over half of all anti-malarial distribution was by
outlets that did not have confirmatory testing available in
the Lao PDR (54%) and Myanmar (59%). Anti-malarial distribution by outlets without confirmatory testing available
occurred primarily in pharmacies in the Lao PDR, where
45.1% of the total markets share was distributed through
outlets without testing. In Myanmar, distribution of antimalarials without confirmatory testing available was common across all private sector outlet types.
Private sector support and engagement

In all three countries with an authorized private sector,
private health facilities and pharmacies more commonly
received some form of support compared to other private
sector outlet types, but some country differences were
observed (Table 6). With regards to training and supervision, in Cambodia and the Lao PDR, over 20% reportedly
received training on malaria diagnosis (Cambodia, 23.9%;
the Lao PDR, 31.7%) or the NTGs (Cambodia, 22.2%; the
Lao PDR, 22.0%). Less than 10% of providers in Myanmar

100
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Fig. 4 Availability of any confirmatory test in the public and private sectors
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Fig. 5 Availability of RDT in the public and private sectorswith and without Quality Assurance status and according to parasite species detection

reportedly received either training. Close to half of the
providers in the Lao PDR (46.7%) reportedly received
some form of supervisory or regulatory visit in the past
12 months. This was lower in Myanmar and Cambodia
(19.9 and 10.6%, respectively). In Myanmar, this supervision was most common among private for-profit facilities
and general retailers.
In terms of access to subsidized commodities, almost
40% of providers in the Lao PDR reported having
received subsidized or free anti-malarials or RDT (antimalarials, 36.2%; RDT, 37.9%). In Cambodia, around 1 in
4 providers reportedly received subsidized anti-malarials
(26.9%) and this was most commonly reported by private
for-profit facilities (40.1%) and pharmacies (52.1%) but
also among itinerant drug vendors (15.0%).
Caseload data reporting was highest in the Lao PDR
(41.9%), common among private for-profit facilities
(65.1%) and pharmacies (55.4%) and negligible or zero
among other outlet types. In Cambodia’s private sector,
17.5% of facilities reportedly report caseload data, and
while most common among private for-profit facilities
(32.4%), also included pharmacies (17.2%), drug stores
(8.2%), and itinerant drug vendors (5.9%). In Myanmar,
private sector caseload reporting was reported among
fewer than 10% of outlets and was most common among
private for-profit facilities (40.3%).

Discussion
Findings from this multi-country study suggest that the
private sector for malaria case management in Cambodia, Myanmar, and the Lao PDR is generally in alignment

with national regulations, treatment guidelines and quality-assurance standards. However, important gaps persist
and pose a threat to national malaria control and elimination goals.
Anti‑malarial availability among informal
and unauthorized private‑sector outlets

In 1995, Thailand banned the sale of anti-malarials in
the private sector as a method of controlling the spread
of drug resistant parasites. Of the 13,000 private-sector
outlets screened during the Thailand survey, only 19 were
found to be stocking anti-malarials. These results suggest
that the long-standing private-sector ban on anti-malarial sales in Thailand has been widely enforced.
The private-sector market composition was substantial
in Cambodia, the Lao PDR, and Myanmar, where onethird or more of anti-malarial service delivery points
were found in the private sector. Unlike Myanmar, where
all private-sector outlet types were authorized to test for
and treat malaria, in Cambodia and the Lao PDR, drug
stores, general retailers, and itinerant drug vendors were
required to refer patients with fever to public-sector outlets, private health facilities, or pharmacies for appropriate care [20]. However, nearly half of the private-sector
providers in Cambodia and approximately one-quarter
in the Lao PDR were unauthorized drug stores, general retailers, or itinerant drug vendors, which typically
lack formal ties to the public health system and national
malaria surveillance systems [15]. Such outlets, therefore, pose a threat to case management according to
NTGs.
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Table 6 Percent of private sector providers that reportedly received malaria case management training within the last
year, supervision within the last year, subsidized anti-malarials and/or malaria RDT, and report caseload data

Cambodia

Private for- profit health
facility
% (CI)

Pharmacy Drug store General retailer Itinerant drug vendor Private sector total
% (CI)
% (CI)
% (CI)
% (CI)
% (CI)

N = 318

N = 99

(29.3, 44.6)

N = 39

N = 235

N = 737

(31.9, 55.4) (7.8, 31.2)

(0.7, 13.8)

(6.3, 13.7)

(19.5, 28.9)

34.8

41.5

3.2

7.3

22.2

(27.1, 43.3)

(31.0, 52.7) (6.8, 30.5)

(0.7, 13.8)

(4.7, 11.3)

(17.8, 27.4)

Supervision or regulatory
visit

18.4

14.7

9.4

0.0

2.9

10.6

(13.8, 24.1)

(7.6, 26.5)

(2.5, 29.8)

–

(1.4, 5.8)

(7.5, 14.7)

Subsidized anti-malarials

37.9

52.9

12.2

0.0

14.3

26.9

(32.1, 44.1)

(43.2, 62.4) (6.1, 22.9)

–

(10.3, 19.5)

(23.0, 31.1)

40.1

52.1

0.0

15.0

29.0

(34.2, 46.2)

(43.9, 60.2) (15.9, 44.1)

–

(10.6, 20.9)

(25.0, 33.3)

32.4

17.2

8.2

0.0

5.9

17.5

(24.2, 41.9)

(9.5, 29.3)

(1.8, 30.1)

–

(3.0, 11.5)

(12.1, 24.5)

N = 94

N = 330

N=6

N = 30

N=5

N = 465

(25.5, 49.3)

(33.1, 53.1) (0.6, 26.1)

(0.6, 19.5)

(2.9, 70.3)

(23.9, 40.7)

23.3

27.7

3.7

21.0

22.0

(16.4, 31.9)

(21.0, 35.5) (6.1, 74.5)

(0.6, 19.5)

(2.9, 70.3)

(16.7, 28.4)

Supervision or regulatory
visit

50.2

62.1

11.5

0.0

46.7

(37.9, 62.5)

(50.4, 72.6) (3.7, 51.0)

(5.7, 21.9)

–

(37.7, 56.0)

Subsidized anti-malarials

41.8

50.4

2.5

0.0

36.2

(28.8, 56.1)

(39.7, 61.0) –

(0.4, 14.5)

–

(27.9, 45.3)

40.4

52.0

2.5

0.0

37.9

(26.7, 55.9)

(40.7, 63.0) (4.1, 73.5)

(0.4, 14.5)

–

(29.2, 47.4)

65.1

54.5

2.5

0.0

41.9

(53.4, 75.2)

(42.7, 65.9) –

(0.4, 14.5)

–

(33.2, 51.1)

N = 354

N = 576

N = 1487

N = 508

N = 2925

(17.4, 27.7)

(7.1, 17.0)

(1.4, 5.0)

(2.3, 6.4)

(5.9, 10.2)

23.6

9.3

(18.1, 29.1)

(4.9, 13.7)

Supervision or regulatory
visit

32.0

16.7

(25.5, 38.6)

(12.7, 20.8)

Report caseload data

40.3

4.7

(31.0, 49.6)

(2.6, 6.9)

Training on malaria
diagnosis
Training on NTGs

Subsidized RDT
Report caseload data
Lao PDR
Training on malaria
diagnosis
Training on NTGs

Subsidized RDT
Report caseload data
Myanmara
Training on malaria
diagnosis
Training on NTGs

36.6

36.6

22.6

43.3

42.8

12.1

N = 46
16.4

15.2

27.8

4.6

30.3
16.7
0.0
25.7
0.0
N/Ab
–
–
–
–

3.2

3.7

3.2

9.3

21.0

4.4

23.9

31.7

8.0

6.4

6.7

9.4

(3.6, 9.3)

(3.4, 9.9)

(6.9, 11.8)

19.2

12.5

19.9

(16.0, 22.3)

(8.6, 16.3)

(17.1, 22.7)

2.4

7.7

9.4

(1.0, 3.8)

(4.3, 11.1)

(6.7, 12.1)

Providers in outlets that have malaria testing and/or treatment available on the day of the survey or in the past 3 months
a

Questions about subsidized anti-malarials and RDT were not asked in Myanmar

b

Drug stores do not exist in Myanmar

Almost half of the private-sector outlets in Cambodia
were unauthorized outlets, which is of importance given
national efforts to increase regulation of the informal private sector as part of the country’s elimination plans. In
2010, the Cambodian government created a new police
force exclusively to impose a ban on private anti-malarial
drug sellers. Previous ACTwatch outlet survey data show

a substantial decline in the relative number of anti-malarial stocking drug stores and general retailers since 2009,
which has largely been attributed to increased regulation of the private sector [4]. However, the current survey
indicates that there are still a substantial number of unauthorized outlets carrying anti-malarials. This may reflect
continued patient demand for case management services
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across different outlet types as well as motivation among
unauthorized providers to provide services to meet the
demand. This may also reflect inadequate capacity of
inspection and judiciary agencies, and a lack of resources
to implement routine inspections as evidenced by other
research [21, 22]. A review by Montagu and Goodman
regarding the regulation of the private sector in developing countries has shown that regulatory approaches
face persistent challenges [23]. Montagu and Goodman
conclude that increased regulatory capacity should be
the medium-term and long-term priority for developing countries and that short-term attention should be
focused on interventions that encourage private providers to improve the quality and coverage of their care, thus
allowing them to advance their own financial interests.
Approximately two-thirds of the unlicensed outlets in
Cambodia were itinerant drug vendors. Although more
research is needed to better understand the role itinerant drug vendors play, the current survey indicates that
these providers were an important community-level
anti-malarial access point [24]. In Cambodia there is evidence that itinerant drug vendors often have some sort
of health qualification and have in the past been, or are
currently affiliated with, public or private health facilities or pharmacies [25]. As such, it may be possible to
formally engage these providers through private-sector
mechanisms. One option would be to integrate these
providers into the formal health system through training,
supervision, business incentives, and accreditation [26].
Several malaria-endemic countries which have incorporated itinerant drug vendors into the private sector have
documented improvements in provider knowledge and
performance [27]. This option further speaks to the recommendations by Montagu and Goodman that would
allow for the improvement of the quality and coverage of
private sector care, while advancing providers’ own financial interests. The integration of itinerant drug vendors
into the formal private sector could be operationalized
through Cambodia’s PPM programme by incorporating
these providers into the existing strategy. As the current PPM mechanism aims to train private providers on
appropriate malaria diagnosis, treatment, and referral
procedures, this would allow for a more regulated inclusion of the private sector in malaria case management
while still adhering to national guidelines [28].
Myanmar represents a unique situation in that a large
majority of the private sector comprises itinerant drug
vendors and general retailers but in contrast to other
GMS countries, these outlet types are permitted to test
for and treat malaria. Private-sector strategies through
the AMTR project in the Eastern part of the country have
leveraged these providers to increase access to qualityassured, subsidized ACT medicines, and more recently
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RDTs [3, 29]. Other supportive strategies have included
engaging with general retailers and itinerant drug vendors through product promoters and provider behaviour
change communication, and several positive outcomes
of these strategies have been documented [3]. However, while these providers have received access to subsidized commodities and supportive interventions, they
are not currently part of a national strategy that actively
registers, trains and supervises these outlets. Furthermore, most private-sector engagement has historically
taken place in the Eastern part of the country. Given this,
Myanmar’s findings do pose some challenges in the context of elimination strategies. In the absence of formally
regulating these private-sector outlets, it will be challenging to routinely monitor and supervise providers,
or obtain malaria surveillance data from them, which is
a cornerstone of elimination strategies [15]. For example,
data from Myanmar’s survey shows that only 3% of general retailers provide any sort of caseload data. The extent
to which these types of outlets can be part of the broader
elimination efforts, in the absence on national strategies
to regulate, train and supervise these providers, needs to
be determined. Initiatives from neighbouring countries
in Cambodia and the Lao PDR, to formally incorporate
such outlets into a programme similar to PPM will be
useful to draw upon.
Alignment of anti‑malarial availability and distribution
with national guidelines

According to NTGs, malaria cases confirmed with
blood testing should be treated with first-line drugs.
Nearly three-quarters of anti-malarial stocking privatesector outlets stocked P. falciparum and P. vivax firstline treatments for uncomplicated malaria in Cambodia
and approximately half of private-sector outlets in the
Lao PDR and Myanmar. In all countries, availability of
P. falciparum and P. vivax first-line treatment was highest in private for-profit health facilities and pharmacies
compared to availability in drug stores, general retailers,
and itinerant drug vendors. The majority of anti-malarials distributed were P. falciparum and P. vivax first-line
treatments in Cambodia (~85%) and Myanmar (~70%),
however, the market share for first-line treatments in the
private sector was very low in the Lao PDR (<10%). These
results suggest that in Cambodia and Myanmar, most
of the anti-malarial distribution was in accordance with
NTGs, but there are notable gaps in the Lao PDR’s private sector.
In the GMS, both P. falciparum and P. vivax malaria
account for a significant proportion of clinical cases [14].
Although first-line treatment for uncomplicated P. falciparum and P. vivax malaria is the same in some countries
(e.g. Cambodia, the Lao PDR), second-line treatment and
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treatment for specific populations (e.g. pregnant women)
differs, necessitating RDT with the capability to differentially diagnose P. falciparum from P. vivax malaria.
Almost all RDT audited during the outlet surveys in
Cambodia, the Lao PDR, Myanmar, and Thailand were
Pf/Pv or Pf/Pan RDT. The small number of RDT audited
in Cambodia, the Lao PDR, and Myanmar that could
only detect P. falciparum malaria were manufactured by
Standard Diagnostics 
(Bioline®) or Orchid Biomedical
®
Systems (Paracheck ). These results suggest that where
RDT testing is available and implemented, providers are
able to identify parasite species to facilitate treatment
according to treatment guidelines.
Misalignment of anti‑malarial availability and distribution
with national guidelines

Within the GMS, adherence to first-line guidelines is
essential. NTGs are regularly updated to reflect the latest evidence on which anti-malarials remain efficacious
for parasite clearance [1]. This is perhaps most notable in
Cambodia, which has seen several revisions to the firstline treatment over the past decade in response to drug
resistant parasites, though recent changes to the NTGs
have been observed across all the study countries. The
continued availability and use of medicines that are not
in the NTGs, or misuse or inappropriate use of secondline treatments in the private sector, not only threatens
effective malaria control, but also national and regional
elimination strategies and goals.
Private‑sector second‑line treatment

Second-line treatment should be utilized only after treatment failure with the first-line drug. Therefore, the availability of the second-line drug should be limited to public
health facilities equipped to detect and manage first-line
treatment failure. Second-line treatment is not expected
to be available within private-sector outlets, especially
pharmacies, drug stores, general retailers, and itinerant
drug vendors that are not trained or authorized to manage treatment failure.
Second-line treatment availability in the private sector was high in the Lao PDR (~75%), low in Myanmar
(~20%), and negligible in Cambodia (<1%). In Myanmar,
second-line treatment accounted for 4% of private-sector market share, whereas in the Lao PDR, second-line
treatment distribution dominated the market, accounting for close to 60% of overall market share and most of
private-sector market share. Such high second-line
treatment market share, despite moderate private sector
availability of first-line P. falciparum and P. vivax treatment, suggests that factors other than availability are
driving private-sector anti-malarial distribution in the
Lao PDR.
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Nearly all second-line treatment distributed in the Lao
PDR was chloroquine, which is indicated for treatment of
P. vivax malaria after AL treatment failure. Chloroquine
should only be stocked at health facilities with the necessary equipment and skilled staff required to detect and
manage treatment failure, however, in the Lao PDR, more
than three-quarters of second-line treatment was distributed at pharmacies. This finding suggests that chloroquine was being used inappropriately to treat patients
presenting for the first time with signs and symptoms of
malaria. Furthermore, it is estimated that close to twothirds of malaria cases in the Lao PDR are P. falciparum
infections [14], which suggests chloroquine could also
have been used to treat patients indiscriminately who
may have P. falciparum malaria, for which chloroquine
has been shown to have high treatment failure rates [30].
Regulation and removal of chloroquine from the
Lao PDR private-sector outlets is urgently needed to
facilitate sale and use of first-line P. falciparum and P.
vivax treatment. Removing this product could be complex given that the majority of chloroquine distributed
in the Lao PDR was M
 araquine® brand, manufactured
locally by CBF Pharma, and included in the national list
of registered medicines [25]. Removing a locally manufactured product from the market could have potential
economic repercussions or provoke political sensitivities. As it is unlikely that local manufacturers will have
the technical expertise, raw materials, quality standards,
and production and laboratory equipment to produce
the first-line ACT treatment [31] or to receive GMP
status to enable purchase of the medicines using international donor funds, other compensation or incentive schemes may be necessary to halt the production
of locally manufactured chloroquine. While some may
argue that there are opportunities to work with local
manufacturers to support the introduction of GMP and
internal quality assurance in local pharmaceutical factories [32], others have concluded that investment to promote local manufacturing of medicines could be better
used to promote health infrastructure [33]. Further
attention is needed to actively engage with the manufacturer and advocate for halting the local distribution
of this product.
Private‑sector treatment that is not in the NTGs

The availability and distribution of treatments that are
not in the NTGs should be carefully assessed, particularly in the context of elimination strategies and goals.
Treatments that are not included in the NTGs, especially
oral artemisinin monotherapy, not only pose a threat to
patient health and safety and have the potential to delay
parasite clearance and drive drug resistance [34, 35],
but also pose a threat to effective malaria control and
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elimination goals. NTGs are regularly updated to reflect
the latest evidence on which anti-malarials remain efficacious for parasite clearance, and thus it is of utmost
importance that patients and providers adhere to these
guidelines.
Availability and market share of treatment not in the
NTGs differed by country and outlet type. In Cambodia
and Myanmar, approximately 1 in 3 private-sector outlets stocked treatment not in the NTGs, accounting for
15 and 25% of private-sector market share, respectively.
In Cambodia, a large majority of this treatment was chloroquine, while in Myanmar, treatment not in the NTGs
was predominantly oral artemisinin monotherapy. The
majority of these treatments in Cambodia and Myanmar
were stocked by general retailers and itinerant drug vendors. Availability of treatment not in the NTGs was lower
in the Lao PDR but still notable, with more than one in
seven private-sector outlets stocking treatment that was
not in the NTGs.
In Myanmar, 14 unique brands of oral artemisinin
monotherapy were audited, primarily at general retailers, pharmacies, and itinerant drug vendors. Unbranded
artesunate tablets manufactured by M
 ediplantex® (Vietnam) accounted for nearly three-quarters of all antimalarials not included in the NTGs. While several
strategies have been in place to remove this medicine
from the market, including the aforementioned AMTR
project and a 2012 ban on oral artemisinin monotherapy,
availability and market share was widespread. Reasons
for the widespread availability and distribution may be
in part attributed to an incomplete ban on oral AMT,
which permits the continued importation of this medicine from manufacturers for up to 5 years from when the
ban was first implemented. Several strategies are urgently
needed to ensure the removal of this medicine, including enforcement of the ban. These could include active
efforts to remove the product from the shelves and/or
communications campaigns to promote provider compliance with the ban [4].
In Cambodia, the majority of audited anti-malarials
that were not in the NTGs were either non-FDC ASMQ,
artemisinin piperaquine, or chloroquine tablets, and of
the nine specific brands audited, none were included in
the country’s drug registry [24]. In 2009, chloroquine was
the first-line P. vivax malaria treatment in Cambodia, but
in 2011, first-line treatment changed to DHA PPQ or
ASMQ after evidence of chloroquine treatment failure
[36]. Audited chloroquine products included N
 itaquin®
manufactured by Utopian and unbranded chloroquine
manufactured by Acdhon, both of which were manufactured in Thailand. The availability of chloroquine
points to the need for tighter regulation, registration of
anti-malarials, and stricter importation laws, including
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tightened importation controls, to ensure these medicines are removed from the market. Measures may also
include passing a law to ban chloroquine from the market, similar to the one passed for oral artemisinin monotherapy, which has been a successful in Cambodia [4].
The current PPM programmes implemented in Cambodia and the Lao PDR provide an opportunity and a
strong foundation to scale up access to first-line treatments in the private sector and remove any unwanted
medicines from the shelves. Similar accreditation programmes that combine training, business incentives,
supervision, and regulatory enforcement have been successful at improving the quality of medicines and services
provided by the private sector [26]. On-going efforts
could be supported with mystery shoppers to check that
providers are only stocking first-line anti-malarials, and
be complemented by increased supervision and regulation to enforce removal of NTG anti-malarials from the
market. In fact, a targeted private-sector intervention in
the Lao PDR involving inspections of the pharmacies,
provision of information on essential medicines, and
distribution of malaria case management documents
found marked improvements in the availability of essential medicines and concluded that these activities were
an important factor behind the service quality improvements [37].
Malaria diagnosis
Availability of any test and market share

Across outlet types and countries, private-sector availability of confirmatory testing among anti-malarial stocking outlets was generally moderate. However, gaps in
testing availability were observed among outlets authorized to test, such as private-for-profit health facilities and
pharmacies across all countries. In Myanmar, availability
was particularly low. Closing gaps in availability of testing and first-line treatment in private sectors across the
GMS is needed to ensure that people seeking treatment
in the private sector are managed according to national
guidelines.
Outlet survey methods do not allow for determining
whether anti-malarials were distributed for confirmed or
unconfirmed cases. However, the audit methodology can
be used to summarize what proportion of anti-malarials
distributed were dispensed by outlets with testing available to the patient. In Cambodia, anti-malarial distribution in both the public and private sectors was typically
occurring in outlets that have confirmatory testing available, which is promising and suggests that testing is at
least available to patients prior to being administered
treatment. However, in the Lao PDR and Myanmar,
the private sector appears to be a source for presumptive treatment. Most anti-malarials were distributed by
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private-sector outlets without confirmatory testing available. This is of particular concern in Myanmar, given that
patients should be given different first-line treatment
regimens according to whether or not they test positive
for P. falciparum or P. vivax. As most anti-malarial distribution occurred through outlets that do not have testing
available suggests that presumptive treatment is rife. Furthermore, while availability of first-line treatments was
high in Myanmar, patients were unlikely to be treated
correctly in the absence of confirmatory testing. As the
NTGs are different for P. falciparum and P. vivax malaria,
adhering to national malaria treatment guidelines was
inherently impossible for most private-sector providers in the absence of confirmatory testing. Moving forward, closing these gaps will be key. Increased coverage
of malaria testing in the private sector will not only be
important to ensure appropriate treatment and rational
drug use, but also to track all confirmed cases towards a
complete national surveillance system.
RDT availability with global quality‑assured standards

The Global Fund to fight AIDS, Tuberculosis and Malaria
(GFATM) periodically publishes a list of quality-assured
RDT that are recommended for use after technical evaluation by the WHO Malaria RDT Testing programme
and/or WHO Prequalification of Diagnostics programme
[38]. Although RDT on this list have been shown to be
accurate and reliable, inclusion does not preclude manufacturing quality failures or degradation due to prolonged
storage or extreme conditions. Furthermore, RDT that
have not been submitted for testing or prequalification
may still meet regulatory standards and are eligible for
procurement by GF principle recipients. Nonetheless, the
GF quality assurance status is viewed as a global standard
for RDT quality.
Most RDT-stocking outlets were stocking qualityassured RDT. However, non quality-assured RDT were
available in 1 in 4 private-sector outlets in Cambodia
and 1 in 5 private-sector outlets in Myanmar. Assured
product quality is important given the variation in RDT
brand performance. In the context of malaria elimination settings, it is imperative that future procurement
of RDT includes only quality-assured products. Non
quality-assured RDT can also leave providers uncertain
about the reliability of results, which in turn can lead to
the over-use of malaria medicines. However, with over
60 manufacturers of malaria RDT, this profusion can
make it difficult for national malaria control programmes
to determine which test or tests to purchase [39]. Continued guidance will be required to assist private-sector
procurement services and private importers to take into
account the quality-assurance status of RDTs when making purchasing and regulatory decisions [40].
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Coverage of private sector engagement and support

Key strategies to ensure that private-sector providers are
contributing to national goals have included training,
supervision, providing access to free or subsidized commodities, and ensuring that the private sector contributes
caseload data to national surveillance systems. As previously discussed, these strategies are being implemented
in various forms across the region, including the PPM
programmes in Cambodia and the Lao PDR. In these
countries, private-sector engagement targets providers
in private for-profit health facilities and pharmacies. In
Myanmar, various strategies are targeted to engage all
private sector outlet types, including general retailers and
itinerant drug vendors.
Results from these outlet surveys show that strategies implemented in each country were not reaching the
majority of private providers. Fewer than half of providers reported receiving any sort of supervisory or regulatory visit within the past year and/or reporting malaria
caseload data to government or non-governmental
organizations. Less than half of the private providers in
Cambodia, the Lao PDR reported access to subsidized
ACT medicines and/or RDT, despite efforts across all
three countries to increase access to subsidized antimalarials through national private-sector distribution schemes. Supervision and caseload reporting were
highest in the Lao PDR and were the result of the current PPM programme. The results from this study point
to the need to scale-up up current PPM programmes in
these countries, to include more licensed providers in the
scheme as a means to ensure universal coverage of testing
and treatment and increased private-sector regulation.
Of promise is that national strategic plans for malaria
elimination in both countries include scale-up and
expansion of the PPM programme [20, 41]. These results
may also serve as a baseline for the much-needed work of
engaging private providers to ensure appropriate malaria
case management and surveillance.
Several lessons can be taken from other pilot initiatives implemented to leverage the private sector in order
to improve access to anti-malarials and RDT to improve
malaria case management. Perhaps most noteworthy
was the affordable medicines facility malaria (AMFm),
which was designed to increase access to affordable quality-assured ACT medicines in both the public and private sectors in eight countries. During the AMFm pilot,
manufacturers were provided copayments to subsidize
wholesale quality-assured ACT medicine prices, and supportive interventions, including provider training and
behaviour change communications were implemented.
An evaluation of the AMFm pilot showed substantial
increases in availability and market share for first-line
treatment for uncomplicated malaria in most countries
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[42]. This was attributed to the subsidy but also several
supportive interventions designed to create awareness
and demand among patients and providers. Future strategies in the GMS designed to maximize coverage of the
first-line treatment may want to consider scaling up supportive interventions to drive provider awareness for
testing and first-line anti-malarial medicines as well as
improving access to subsidized first-line treatments.
Improved private-sector malaria case reporting will also
be important not only so that patients can be tracked and
managed appropriately but also to ensure complete and
timely case reporting [1]. This is especially important in
elimination settings such as the GMS, where all cases must
be tracked and investigated. Results from this study indicate that the majority of private-sector providers engaging
in malaria testing and treatment do not provide malaria
caseload data to a government authority or non-governmental organization across countries. Several challenges
have been identified with incorporating the private sector
into malaria surveillance systems [15]. Several initiatives
are underway in Cambodia, the Lao PDR, and Myanmar
to improve private-sector case management practices and
ensure caseload reporting as part of the GMS Elimination
of Malaria through Surveillance (GEMS) project in Cambodia, the Lao PDR, Myanmar, and Vietnam. The GEMS
project includes provider training and supervision and
strategies to strengthen private sector surveillance [43].
Caseload data from the private sector will be integrated
with public-sector data to provide national programmes
with a more complete picture of malaria burden and information to respond to all detected cases.
Strengths and limitations

The ACTwatch project has conducted approximately 50
outlet surveys in 12 countries in Africa and Asia. The
outlet survey methodology is rigorous and uses standardized methods and data collection tools across countries and over time. The use of a full census of all outlets
with the potential to stock anti-malarials and/or malaria
RDT allows for a unique analysis of the total malaria
testing and treatment market. The surveys conducted
in the GMS provide useful information that can be used
to support national policy towards malaria control and
elimination.
Several limitations should be considered when interpreting ACTwatch outlet survey results [16, 19], as with
other medicine surveys [44]. This includes the crosssectional nature of the surveys, potentially biased or
misreported information, and challenges related to
standardizing anti-malarial volumes and prices for products with different active ingredients and formulations.
Providers may hide anti-malarials, especially providers
who are not authorized to provide testing and treatment
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(e.g. general retailers), or providers who stock banned
anti-malarials that are illegal to distribute (e.g. oral artemisinin monotherapy). This may be more common in
malaria elimination settings where more resources are
earmarked for enforcement of regulation [44]. Mystery
client surveys may be an important source of data to triangulate results from the outlet surveys, particularly with
respect to stocking practices of banned products when
total market data is not needed. Finally, the outlet surveys
conducted in the GMS were designed to generate results
for key indicators including malaria testing and treatment
availability, market share, and private-sector engagement
and support and were not intended to evaluate specific
programmes such as the PPM initiatives in the Lao PDR
and Cambodia. Specific study designs with appropriate
sampling techniques would be needed to determine the
effectiveness and impact of these interventions.

Conclusion
Findings from this multi-country study suggest that the
private sector for malaria case management in Cambodia, Myanmar and the Lao PDR is generally in alignment
with national regulations, treatment guidelines, and RDT
quality-assurance standards. However, important gaps
persist and pose a threat to national malaria control and
elimination goals. In 2015, there was still a substantial
amount of treatment not included in the NTGs stocked
and distributed in Cambodia and Myanmar, as well as
inappropriately high distribution of second-line P. vivax
malaria treatment in the Lao PDR. As malaria elimination efforts intensify, it will be important to enforce
removal of these products from private-sector outlets
and to ensure only authorized outlets are providing
malaria testing and treatment services. Decisions about
whether or not informal providers warrant inclusion into
the formal health system need to be made. Private-sector
engagement was inadequate in Cambodia, the Lao PDR,
and Myanmar. Increased engagement has the potential
to improve malaria case management, readiness, and
case reporting, and is thus critical for continued progress
towards malaria elimination goals in the GMS.
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